Another critical indication for HSCT is a presence of a mutation in CSF3R or RUNX1 genes within the bone marrow of patients with SCN, which significantly increases the risk of development of MDS/AML (99). The gene discussed is CSF3R; the disease is myelodysplastic syndrome.